Ho Dong Yang
Woorilife & Health
3 Biryong-ro 464beon-gil
Hwado-eup
Namyangju-si
Gyeonggi-do
12033
South KoreaFEI 3014653532Issued Dec 28, 2023Center for Drug Evaluation and Research | CDER
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3014653532.
Violations3
Issue DateDec 28, 2023
Product TypeDrugs
StatusOpen
Letter Details
Firm
Woorilife & Health
Location
Ho Dong Yang
Woorilife & Health
3 Biryong-ro 464beon-gil
Hwado-eup
Namyangju-si
Gyeonggi-do
12033
South Korea
FEI Number
3014653532
Country
South Korea
Issue Date
December 28, 2023
Issuing Office
Center for Drug Evaluation and Research | CDER
Product Type
Drugs
Status
Open
Summary
Woorilife & Health, a South Korean manufacturer of over-the-counter drug products including toothpaste, failed to conduct required identity testing on incoming components at high risk of contamination with diethylene glycol (DEG) or ethylene glycol (EG), specifically glycerin, propylene glycol, and sorbitol solution, in violation of 21 CFR 211.84(d)(1). The facility's manufacturing methods, facilities, and controls did not conform to Current Good Manufacturing Practice (CGMP) regulations, resulting in the company's drug products being deemed adulterated under the Federal Food, Drug, and Cosmetic Act. The violations were identified following FDA's review of records submitted in response to two separate inspection requests in February and July 2023.
Woorilife & Health FDA Warning Letter, December 28, 2023